A randomized, open-label, phase II open platform study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATForM)

Authors :: Paul Nathan
Dirk Schadendorf
Eduard Gasal
P.A. Ascierto
A. Ribas
Aislyn Boran
R. Dummer
J.B.A.G. Haanen
Jeffrey S. Weber
Georgina V. Long
C. Robert
A. Arance
Bettinger S
Anthony D'Amelio
Source :: Annals of Oncology. 29:viii465-viii466
Publication Year :: 2018
Publisher :: Elsevier BV, 2018.

Subjects :: Oncology
medicine.medical_specialty
Open platform
Metastatic melanoma
business.industry
Internal medicine
Medizin
medicine
Hematology
Open label
Previously treated
business

Tools